Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5year follow-up

Ferrer, Montse; Guedea, Ferrán; Suárez, José Francisco; Paula, Belen de; Macías, Víctor; Mariño, Alfonso; Hervás, A.; Herruzo, Ismael; Ortiz, M.; León, Javier Ponce de; Sancho, Gemma; Boladeras, A.; Ayala, Adriana; Craven-Bratle, Jordi; Ávila, Mónica; Cunillera, Oriol; Pardo, Yolanda; Alonso, Jordi; Aguiló, F

doi:10.1016/j.radonc.2013.05.038

Cited by 77 publications

(70 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Permanent low dose rate brachytherapy is a well-established treatment option for early prostate cancer [1] with advantages over other options in terms of improved sexual, bowel and urinary function in the long term [2]. In early prostate cancer improved PSA control with radiation dose escalation has been demonstrated in randomised trials using external beam radiotherapy [3] and in multi-institutional series of cohorts treated with permanent prostate brachytherapy [4].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

et al. 2015

View full text Add to dashboard Cite

Aims To examine the relationship between post-implant CT dosimetry and long term PSA relapse free survival in patients treated with Iodine 125 LDR prostate brachytherapy as monotherapy and secondly, to audit recent practice against RCR guidelines following the re-introduction of post-implant dosimetry for all patients in our centre. Similarly an increase in the mean (SD) V100 from 92 (4.4) % to 95 (3.2) % is noted over time. No difference between clinicians was noted. Henry et al. 3 Conclusion D90 values of less than 140Gy continue to be predictive of increased risk of recurrence of prostate cancer across risk groups with longer follow-up. Quality assurance can be used to ensure improved and consistent implant quality in a team with multiple clinicians. Methods and Materials

show abstract

Section: Introductionmentioning

confidence: 99%

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Consequently, PPB is often the preferred modality in low-risk patients, particularly because the available evidence suggests that brachytherapy presents a lower risk of incontinence and impotence compared with surgery and better sparing of healthy tissues when compared with EBRT (5,6).…”

Section: Introductionmentioning

confidence: 99%

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Symptoms such as urinary urgency, increased urinary frequency and nocturia are characteristic of UUI. Other study [10] also found that late side effects can be particularly more relevant in chronic lesions in adjacent tissues.…”

Section: Discussionmentioning

confidence: 84%

“…A prospective cohort study evaluated the QoL of men with PC who underwent RP or RT. Starting with the pre-treatment and a follow-up examination up to five years afterward, 704 patients with localized PC (low or intermediate risk) were recruited between 2003 and 2005 by Ferrer and collaborators [10]. QoL was assessed by the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the physiological repercussions, post-RT pelvic symptoms may restrict daily living activities (DLA), social interactions, and self-perception of health. The greatest problems are related to social and mental well-being, which may have psychological, physical, professional, social, and sexual repercussions with a significant impact on QoL [9,10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pelvic symptoms after radiotherapy in prostate cancer: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

Introduction: Despite the technical and scientific progress that improved therapeutic resources available in Oncology, adverse effects of treatment can be prominent, impacting the quality of life (QoL). Objective: This research aims to determine the prevalence of post-radiotherapy pelvic symptoms in prostate cancer (PC) and its impact on QoL. Methods: We assessed three groups of patients at different stages during radiotherapy (RT): Pre-RT, evaluated before of RT; Post-RT#1, evaluated between six months and one year post-RT; Post-RT#2, evaluated between two and a half and four years post-RT. The presence of urinary incontinence (UI), its characteristics and impact on daily living activities (DLA) were evaluated by ICIQ-SF questionnaire. WHOQOL-BREF questionnaire was used to assess QoL. Student t test was used, considering significant p < 0.05. Results: Thirty-three men were assessed (pre-RT, n = 12; Post-RT#1, n = 10; Post-RT#2, n = 11). The prevalence of lower urinary tract symptoms (LUTS) was highest in Post-RT#1 group. Post-RT#2 group had the highest * RAM: Doctoral student, e-mail: alinemrib@gmail. prevalence of post-RT UI. In QoL, Pre-RT and Post-RT#2 groups experiencing the greatest impact on physical, environmental and overall QoL. Conclusion: Acute effect of RT is characterized by a high prevalence of LUTS. Post-RT#2 group experienced the most adverse effects on DLA due to a higher prevalence of post-RT UI. n = 12; n = 10; n = 11

show abstract

Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5year follow-up

Cited by 77 publications

References 43 publications

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

Pelvic symptoms after radiotherapy in prostate cancer: a cross-sectional study

Contact Info

Product

Resources

About